PDF(Pubmed)
Abstract：
BACKGROUND: Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid carcinoma, and Hashimoto\'s thyroiditis (HT) has been postulated to have a relationship with PTC. This study aims to assess clinical and pathological characteristics of patients with papillary thyroid carcinoma coexisting with Hashimoto\'s thyroiditis.
METHODS: A retrospective study was conducted in a cohort of patients with thyroid carcinoma at the Department of Surgery, Shanghai General Hospital from January 2017 to December 2018. Medical records of patients who had PTC with or without HT were reviewed and clinical and histopathological characteristics of these patients were analyzed.
RESULTS: A total of 632 patients with thyroid carcinoma were identified. Among them, 614 (97.15%) had PTC and 120/614 (19.0%) harbored PTC together with HT. PTC was significantly associated with HT, as compared with other histological subtypes (P < .001). Patients with coexisting PTC and HT (PTC + HT group) were significantly younger than patients with PTC alone (PTC group) (P = .008). There were more women in the PTC + HT group than in the PTC group (88.3% vs. 73.1%, P < .001). TSH, TGAb, and TPOAb levels were significantly higher in the PTC + HT group than in the PTC group (P ≤ .001). In addition, tumor diameter was smaller in the PTC + HT group than in the PTC group (P = .034). The PTC + HT group showed a significant better recurrence-free survival than the PTC group. Furthermore, immunohistochemical analysis revealed that patients in the PTC + HT group had a higher positive rate and higher expression intensity of Ki67 than patients in the PTC group.
CONCLUSIONS: Our study revealed that patients with coexisting PTC and HT were younger, had smaller tumor diameters, a better prognosis, and higher positive rates and expression intensity of Ki67, than did patients with PTC alone.
METHODS: A retrospective study was conducted in a cohort of patients with thyroid carcinoma at the Department of Surgery, Shanghai General Hospital from January 2017 to December 2018. Medical records of patients who had PTC with or without HT were reviewed and clinical and histopathological characteristics of these patients were analyzed.
RESULTS: A total of 632 patients with thyroid carcinoma were identified. Among them, 614 (97.15%) had PTC and 120/614 (19.0%) harbored PTC together with HT. PTC was significantly associated with HT, as compared with other histological subtypes (P < .001). Patients with coexisting PTC and HT (PTC + HT group) were significantly younger than patients with PTC alone (PTC group) (P = .008). There were more women in the PTC + HT group than in the PTC group (88.3% vs. 73.1%, P < .001). TSH, TGAb, and TPOAb levels were significantly higher in the PTC + HT group than in the PTC group (P ≤ .001). In addition, tumor diameter was smaller in the PTC + HT group than in the PTC group (P = .034). The PTC + HT group showed a significant better recurrence-free survival than the PTC group. Furthermore, immunohistochemical analysis revealed that patients in the PTC + HT group had a higher positive rate and higher expression intensity of Ki67 than patients in the PTC group.
CONCLUSIONS: Our study revealed that patients with coexisting PTC and HT were younger, had smaller tumor diameters, a better prognosis, and higher positive rates and expression intensity of Ki67, than did patients with PTC alone.
摘要：
背景：甲状腺乳头状癌（PTC）是甲状腺癌最常见的亚型，桥本甲状腺炎（HT）被认为与PTC有关。本研究旨在评估甲状腺乳头状癌合并桥本甲状腺炎患者的临床和病理特征。
方法：对外科甲状腺癌患者进行了一项回顾性研究，2017年1月至2018年12月，上海市总医院。回顾了患有或不患有HT的PTC患者的病历，并分析了这些患者的临床和组织病理学特征。
结果：共发现632例甲状腺癌患者。其中,614（97.15％）具有PTC，120/614（19.0％）具有PTC和HT。PTC与HT显著相关,与其他组织学亚型相比（P<0.001）。同时存在PTC和HT的患者（PTC+HT组）明显小于单纯PTC患者（PTC组）（P=.008）。PTC+HT组的女性多于PTC组(88.3%vs.73.1%,P<.001)。TSH,TGAb,PTC+HT组TPOAb水平明显高于PTC组(P≤0.001)。此外,PTC+HT组的肿瘤直径小于PTC组(P=.034)。PTC+HT组的无复发生存率明显优于PTC组。此外，免疫组化分析显示，PTC+HT组患者的Ki67阳性率和表达强度均高于PTC组。
结论：我们的研究表明，PTC和HT并存的患者年龄较小，肿瘤直径较小，更好的预后，Ki67的阳性率和表达强度高于单纯PTC患者。
方法：对外科甲状腺癌患者进行了一项回顾性研究，2017年1月至2018年12月，上海市总医院。回顾了患有或不患有HT的PTC患者的病历，并分析了这些患者的临床和组织病理学特征。
结果：共发现632例甲状腺癌患者。其中,614（97.15％）具有PTC，120/614（19.0％）具有PTC和HT。PTC与HT显著相关,与其他组织学亚型相比（P<0.001）。同时存在PTC和HT的患者（PTC+HT组）明显小于单纯PTC患者（PTC组）（P=.008）。PTC+HT组的女性多于PTC组(88.3%vs.73.1%,P<.001)。TSH,TGAb,PTC+HT组TPOAb水平明显高于PTC组(P≤0.001)。此外,PTC+HT组的肿瘤直径小于PTC组(P=.034)。PTC+HT组的无复发生存率明显优于PTC组。此外，免疫组化分析显示，PTC+HT组患者的Ki67阳性率和表达强度均高于PTC组。
结论：我们的研究表明，PTC和HT并存的患者年龄较小，肿瘤直径较小，更好的预后，Ki67的阳性率和表达强度高于单纯PTC患者。
